Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment

A Phase 1, Open-label Study to Evaluate the Pharmacokinetics and Safety of Single Doses of VX-548 in Subjects With Severe or Moderate Renal Impairment and in Matched Healthy Subjects

The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of VX-548 and its metabolite in participants with severe or moderate renal impairment and healthy participants.

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4) (A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

Key Inclusion Criteria:

• Cohorts 1 and 3: Participants with Severe or Moderate Renal Impairment

  • Body mass index (BMI) of greater than or equal to (>=)18.0 to less than (<) 40.0 kilogram per square meter (kg/m^2)
  • Stable renal function as pre-defined in the protocol

• Cohorts 2 and 4: Matched Healthy Participants

  • Healthy participants will be matched to Cohorts 1 and 3 participants according to each of the following parameters: sex, age (±10 years), and BMI (±15%)

Key Exclusion Criteria:

• Cohorts 1 and 3: Participants with Severe or Moderate Renal Impairment

  • Hemoglobin less than or equal to (≤) 9.0 gram per deciliter (g/dL) at screening

• Cohorts 2 and 4: Matched Healthy Participants

  • Prior renal transplantation, prior hemodialysis, or prior peritoneal dialysis

• All Cohorts:

  • History of febrile or acute illness that has not fully resolved by 14 days before study drug dosing.
  • Any condition possibly affecting drug absorption

Other protocol defined Inclusion/Exclusion criteria may apply.